This observation lines up with the lower trend to increase VAF over time and to acquire new mutations in DNMT3A-driven CHIP, both in patients developing t-MN and in healthy individuals, as shown by Van Zeventer et al. [34], and a lower risk of myeloid malignancy when compared to other genotypes [50]. This evidence concerns the gene DNMT3A and therapy-related myeloid neoplasm.